Related Experiment Video
Updated: Mar 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site
Tindara Franchina1,2, Alessandro Russo1,2, Giuseppina Rosaria Ricciardi1,2
1a Medical Oncology Unit, A.O. Papardo , Messina , Italy.
Abstract:
During the last decade the therapeutic landscape of Non Small Cell Lung Cancer (NSCLC) has profoundly changed with the identification of actionable genetic alterations that defined molecularly selected subgroups of patients with specific clinic-pathological characteristics and increased sensitivity to specific targeted agents. The presence of ROS1 rearrangements defines a small subgroup of lung adenocarcinomas (∼1-2%) with peculiar clinic-pathological characteristics and increased sensitivity to Crizotinib. It has been reported that ROS1-tranlslocated NSCLCs may also respond well to Pemetrexed-based chemotherapy. Moreover, patients with oncogene-addicted NSCLC may present peculiar pattern of metastatization and, in some instances, are associated with unusual site of metastases. Herein, we present a case of a young woman with bilateral ovarian metastases from a ROS1-positive adenocarcinoma of the lung with a lengthy progression-free survival on Pemetrexed-containing chemotherapy.
Insights
This case study highlights a rare instance of bilateral ovarian metastases in a young woman with ROS1-positive Non Small Cell Lung Cancer (NSCLC). The patient achieved prolonged progression-free survival with Pemetrexed-based chemotherapy.
Area of Science:
- Oncology
- Genetics
- Pulmonology
Background:
- Non Small Cell Lung Cancer (NSCLC) treatment has evolved with targeted therapies for specific genetic alterations.
- ROS1 rearrangements identify a small subset of lung adenocarcinomas (1-2%) sensitive to Crizotinib.
- ROS1-translocated NSCLCs may also respond to Pemetrexed-based chemotherapy and present with unusual metastatic patterns.
Purpose of the Study:
- To report a case of bilateral ovarian metastases in a patient with ROS1-positive lung adenocarcinoma.
- To illustrate the potential efficacy of Pemetrexed-containing chemotherapy in such cases.
Main Methods:
- Case report of a young woman with ROS1-positive lung adenocarcinoma.
- Analysis of clinic-pathological characteristics and treatment response.
Main Results:
- The patient presented with bilateral ovarian metastases.
- A lengthy progression-free survival was achieved with Pemetrexed-containing chemotherapy.
Conclusions:
- Ovarian metastases can occur in ROS1-positive lung adenocarcinoma.
- Pemetrexed-based chemotherapy may offer a viable treatment option for ROS1-translocated NSCLC with unusual metastases.
More Related Videos
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018